Sixfold Bioscience
Sixfold Bioscience is a venture-backed preclinical-stage biotechnology company based in London, UK, focused on solving the critical challenge of RNA delivery. Using advanced AI, Bayesian Optimization, automated chemistry, and high throughput screening, they develop programmable drug delivery systems, particularly for short interfering RNA (siRNA) and messenger RNA (mRNA). Their innovative platform, Mergo®, is inspired by natural RNA delivery mechanisms and aims to unlock new cell types for treatment, expanding the potential of RNA therapeutics beyond traditional targets like the liver.
Industries
Nr. of Employees
small (1-50)
Products
Mergo® platform
An AI-powered, evolution-inspired RNA delivery platform designed to target a wide range of tissues and cell types, beyond the liver.
RNA therapeutics (siRNA, mRNA)
Programmable RNA-based drugs for gene silencing and gene expression, with a focus on expanding therapeutic applications.
Mergo® platform
An AI-powered, evolution-inspired RNA delivery platform designed to target a wide range of tissues and cell types, beyond the liver.
RNA therapeutics (siRNA, mRNA)
Programmable RNA-based drugs for gene silencing and gene expression, with a focus on expanding therapeutic applications.
Services
RNA delivery platform development
Development of programmable drug delivery systems for RNA therapeutics, including siRNA and mRNA, using AI and automated chemistry.
Preclinical research and development
Conducting preclinical studies to evaluate the efficacy and safety of RNA delivery systems and therapeutics.
RNA delivery platform development
Development of programmable drug delivery systems for RNA therapeutics, including siRNA and mRNA, using AI and automated chemistry.
Preclinical research and development
Conducting preclinical studies to evaluate the efficacy and safety of RNA delivery systems and therapeutics.